Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 6/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.77 |
| ▸ | MMP2 | P08253 | 6/20 | 0.77 |
| ▸ | CTSK | P43235 | 11/20 | 0.70 |
| ▸ | CTSS | P25774 | 10/20 | 0.70 |
| ▸ | CTSB | P07858 | 9/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | MMP9 | P14780 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896532 | 0.85 | CTSK (0.64) | ADAM10ERBB2MMP2CTSKCTSS | |
| SCHEMBL6394484 | 0.85 | CTSK (0.64) | ADAM10ERBB2MMP2CTSKCTSS | |
| SCHEMBL8115758 | 0.81 | CTSK (1.00) | CTSKCTSSCTSBKCNH2 | |
| SCHEMBL4899778 | 0.78 | CTSK (0.89) | CTSKCTSSCTSBKCNH2 | |
| SCHEMBL2174006 | 0.77 | ADAM10 (0.61) | ADAM10ERBB2MMP2MMP9 | |
| SCHEMBL3458216 | 0.77 | ADAM10 (0.61) | ADAM10ERBB2MMP2MMP9 | |
| SCHEMBL4894615 | 0.77 | CTSK (0.87) | CTSKCTSSCTSBKCNH2 | |
| SCHEMBL26706252 | 0.76 | MAPT (0.69) | LMNATSHRKMT2A | |
| SCHEMBL4891813 | 0.75 | CTSK (0.65) | ADAM10ERBB2MMP2CTSKCTSS | |
| SCHEMBL4889472 | 0.74 | CTSK (0.77) | ADAM10ERBB2MMP2CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345677-B2 | Compositions, methods and kits relating to HER-2 cleavage | INCYTE CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| EP-1613269-B1 | COMPOSITIONS, METHODS AND KITS RELATING TO HER-2 CLEAVAGE | INCYTE CORP (US) | 2015-02-25 | — | — | EP | disclosed |
| US-20120263676-A1 | COMPOSITIONS, METHODS AND KITS RELATING TO HER-2 CLEAVAGE | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-10-18 | — | — | US | disclosed |
| US-8088737-B2 | Treating a cancer, in particular breast cancer, that overexpresses Her-2 by administering an ADAM inhibitor; novel variants of ADAM15 and ADAM15; synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds | INCYTE CORPORATION (US) | 2012-01-03 | — | — | US | disclosed |
| US-20040247602-A1 | Compositions, methods and kits relating to Her-2 cleavage | INCYTE CORPORATION | 2004-12-09 | — | — | US | disclosed |